Florida Fails to Pass Amendment Legalizing Recreational Weed
By Robin Foster HealthDay Reporter
WEDNESDAY, Nov. 6, 2024 -- A ballot measure to legalize the recreational use of marijuana in the state of Florida failed on Tuesday.
While 55.9% of Florida voters backed the proposed amendment, it did not reach the 60% threshold needed to make the initiative part of the state's constitution.
"With the rejection of Amendment 3, Floridians have taken a firm stance against the dangerous drugs the pot profiteers tried to convince the public are harmless," Kevin Sabet, president of Smart Approaches to Marijuana, which opposes marijuana legalization, said in a statement.
“Amendment 3 was bad for Florida and even worse for Floridians,” Mark Wilson, president and CEO of the Florida Chamber of Commerce, said in a statement. “This pro-drug amendment was bad for our kids, bad for our communities, bad for our local business, and ultimately bad for Florida.”
David Culver, senior vice president of the U.S. Cannabis Council, told the Washington Post that the supermajority threshold required by Florida was too much to overcome this election.
“This isn’t the end in Florida, it’s just the beginning since we’ve now seen how strongly the push for legalization resonates in the state,” Culver added.
Florida wasn't the only state to say no to recreational marijuana this election: Voters in North Dakota and South Dakota appear to have again rejected similar measures, the Post reported.
Meanwhile, voters in Nebraska handily approved two measures legalizing medical marijuana, though a judge could invalidate those results in the coming weeks, the Post reported.
Psychedelics, which have been touted by some as a potential treatment for depression and other mental health issues, also took a hit in the polls: In Massachusetts, voters rejected a measure that would have legalized plant psychedelics such as magic mushrooms for therapeutic use. Oregon and Colorado have already passed such laws, the Post reported.
At the moment, recreational marijuana is legal in 24 states and Washington, D.C., amid dramatic shifts in public attitudes about the drug. Gallup polling last year reported that a record 70% of voters support marijuana legalization.
Although marijuana remains illegal at the federal level, the Biden administration is seeking to loosen restrictions, but skeptics argue that high-potency marijuana products pose a risk to youth brain development and up the chances for addiction.
The Biden measure would not legalize marijuana at the federal level, but instead place it in the less dangerous tier of controlled substances that includes prescription ketamine and testosterone. That move could boost research into marijuana’s health benefits by easing federal restrictions for studying the drug.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-11-07 00:00
Read more
- First Cases of Sexually Transmitted Ringworm Reported in the U.S.
- One Day of the Week Has Highest Suicide Risk
- Nitrofurantoin, Cranberry Products May Cut UTI Episodes in Children
- Parents or Ambulance: How a Child Reaches an ER Could Matter
- LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia
- Elevar Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for Rivoceranib in Combination with Camrelizumab as a First-line Systemic Treatment for Unresectable Hepatocellular Carcinoma
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions